Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex

Biochemical Pharmacology

Volumn 59, Issue 4, 2000, Pages 329-336

  Sugiyama, Katsumi ^a   Chen, Zhou ^a   Lee, Yong S ^a   Kador, Peter F ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Aldose reductase; Aldose reductase inhibitors; Diabetes; Mechanism of action; Non covalent binding

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; IMIRESTAT; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PONALRESTAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TOLRESTAT;

ARTICLE; BINDING SITE; COMPLEX FORMATION; ENZYME INHIBITION; IN VITRO STUDY; MOLECULAR MODEL; PH; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; ANIMALS; ENZYME INHIBITORS; FLUORENES; HUMANS; HYDANTOINS; LENS, CRYSTALLINE; MODELS, MOLECULAR; MUSCLES; NADP; NAPHTHALENES; PHTHALAZINES; RATS;

EID: 0033975861     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00332-9     Document Type: Article

References (28)

1. Kinoshita J.H. Aldose reductase in the diabetic eye. XLIII Edward Jackson Memorial Lecture. Am J Ophthalmol. 102:1986;685-692.
2. Kador P.F. The role of aldose reductase in the development of diabetic complications. Med Res Rev. 8:1988;325-352.
3. Neuenschwander H., Takahashi Y., Kador P.F. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther. 13:1997;517-528.
4. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors The end of an era or the need for different trial designs? Diabetes. 46:(Suppl 2):1997;82-89.
5. Spielberg S.P., Shear N.H., Cannon M., Hutson N.J., Gunderson K. In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann Intern Med. 114:1991;720-724.
6. Wilson D.K., Bohren K.M., Gabbay K.H., Quiocho F.A. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 257:1992;81-84.
7. Rondeau J.-M., Tête-Favier F., Podjarny A., Reymann J.-M., Barth P., Biellmann J.-F., Moras D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature. 355:1992;469-472.
8. Wilson D.K., Tarle I., Petrash J.M., Quiocho F.A. Refined 1,8 Å structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci USA. 90:1993;9847-9851.
9. Wilson D.K., Nakano T., Petrash J.M., Quiocho F.A. 1.7 Å structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor. Biochemistry. 34:1995;14323-14330.
10. Urzhumtsev A., Tete-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L., Biellmann J.-F., Podjarny A., Moras D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure. 5:1997;601-612.
11. Kador P.F., Sharpless N. Aldose reductase inhibitors A potential new class of agents for the pharmacological control of certain diabetic complications . J Med Chem. 28:1985;841-849.
12. Lee Y.S., Pearlstein R., Kador P.F. Molecular modeling studies of aldose reductase inhibitors. J Med Chem. 37:1994;787-792.
13. Lee Y.S., Chen Z., Kador P.F. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg Med Chem. 6:1998;1811-1819.
14. Lee Y.S., Sugiyama K., Kador P.F. Rotamers of tolrestat and their binding mode to aldose reductase. Adv Exp Med Biol. 463:1999;465-472.
15. Jaquinod M., Potier N., Klarskov K., Reyman J.M., Sorokine O., Kieffer S., Barth P., Andriantomanga V., Biellmann J.-F., Van Dorsselaer A. Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. Eur J Biochem. 218:1993;893-903.
16. Potier N., Barth P., Tritsch D., Biellmann J.-F., Van Dorsselaer A. Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Adv Exp Med Biol. 414:1997;453-454.
17. Potier N., Barth P., Tritsch D., Biellmann J.-F., Van Dorsselaer A. Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Eur J Biochem. 243:1997;274-282.
18. Sato S., Old S., Carper D., Kador P.F. Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Adv Exp Med Biol. 372:1995;259-268.
19. Sato S., Kador P.F. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem Pharmacol. 40:1990;1033-1042.
20. Segel IH, Enzyme Kinetics, pp, 25-29 and 218-220. Wiley-Interscience Publications, New York, 1975.
21. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. A program for macromolecular energy minimizations and molecular dynamics calculations. J Comput Chem. 4:1983;187-217.
22. Molecular Simulation Inc., Parameter file for CHARMm version 22, Waltham, MA, 1992.
23. Grimshaw C.E., Shahbaz M., Putney C.G. Mechanistic basis for nonlinear kinetics of aldehyde reduction catalyzed by aldose reductase. Biochemistry. 29:1990;9947-9955.
24. Grimshaw C.E., Bohren K.M., Lai C.-J., Gabbay K.H. Human aldose reductase pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition . Biochemistry. 34:1995;14374-14384.
25. Liu S.Q., Bhatnagar A., Srivastava S.K. Does sorbinil bind to the substrate binding site of aldose reductase? Biochem Pharmacol. 44:1992;2427-2429.
26. +/NADPH and alrestatin-like inhibitors . Biochemistry. 33:1994;7157-7165.
27. Nakano T., Petrash J.M. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Biochemistry. 35:1996;11196-11202.
28. Lee H.-K., Querijero G. Kinetics and mechanisms of thioamide rotational isomerism N-thionaphthoyl-N-methyl glycine derivative . J Pharm Sci. 74:1985;273-276.